As per terms of the agreement, Alliance Lithomobile will be responsible for capital sales of the Sonablate when appropriate. Misonix and Alliance Lithomobile will share the ‘fee for use’ revenue for the length of the agreement plus an additional three years. Purchase minimums for both ‘fee per use’ and capital sales are part of the agreement.
“Misonix is pleased to partner with Lithomobile to provide prostate HIFU treatment for prostate cancer to hospitals throughout Italy. Lithomobile’s reputation as a high-profile distributor of advanced medical equipment in Italy is well known to us,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “Lithomobile’s experience with the mobile fee for service business segment makes Lithomobile a particularly appealing distribution partner, whose strengths blend well with Misonix’s business strategy for HIFU.”